Symphogen A/S

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Symphogen A/S sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

Symphogen A/S: 12 sponsored US clinical trials, none currently recruiting.

Symphogen A/S sponsors 12 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Cancer, with 2 trials.

Top-decile sponsor footprint

Symphogen A/S ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 27/100

9 of 12 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (75.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

12 total, page 1 of 1

COMPLETED Phase 1

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

NCT04672434
COMPLETED Phase 1

Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies

NCT04641871
TERMINATED Phase 2

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

NCT03549338
COMPLETED Phase 1

Sym023 (Anti-TIM-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03489343
COMPLETED Phase 1

Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03489369
COMPLETED Phase 1

Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas

NCT03311412
TERMINATED Phase 1

Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

NCT02906670
TERMINATED Phase 1

Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients

NCT02568046
COMPLETED Phase 1

Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies

NCT02648724
COMPLETED Phase 2

Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer

NCT02083653
COMPLETED Phase 1

Sym004 in Patients With Advanced Solid Tumors

NCT01117428
COMPLETED Phase 2

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

NCT00718692

Phase Distribution

PhaseTrial count
Phase 1 9
Phase 2 3

Therapeutic Areas

Metastatic Cancer 2
Solid Tumor 2
Lymphoma 2

How the Symphogen A/S early-phase archive is shaped

12 indexed studies, none listed as recruiting (0% open); 9 completed (75%).

Phase mix: 0 late (III/IV) vs 12 early (I/II) (early-phase heavy).

Top condition: Metastatic Cancer (2 trials), 2 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Symphogen A/S: archived-pipeline peers nationwide

Peers matched on 12 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Symphogen A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20% Total trials Recruiting share Symphogen A/SAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.Angiodynamics10xBio22nd Century Group23andMe3-C Institute for Social Development
Symphogen A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Symphogen A/S sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Symphogen A/S page

12 registered trials is a research-attention snapshot, not an endorsement of Symphogen A/S or any single study.

  • None of Symphogen A/S's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Metastatic Cancer is the condition Symphogen A/S studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Symphogen A/S pipeline card: 12 registered trials from official public datasets.Report a data error.